Berlin Heals Holding AG, a late stage medtech startup developing a groundbreaking method and medical device for treating heart failure, has secured fresh funding in its series A round to support further clinical developments. The company’s initial product, C-MIC, has already demonstrated success in a pilot study with patients and recently completed enrollment in an international multi-center controlled randomized clinical trial for CE certification..

柏林医疗控股公司（Berlin Heals Holding AG）是一家处于后期阶段的医疗技术初创公司，正在开发一种突破性的心力衰竭治疗方法和医疗设备，现已在其A轮融资中获得新资金，以支持进一步的临床开发。该公司首款产品C-MIC已在患者试点研究中取得成功，并刚刚完成了一项国际多中心随机对照临床试验的入组，以获取CE认证。

Berlin Heals

柏林愈合

has developed a revolutionary implantable device called 'C-MIC' (Cardiac Microcurrent), which uses a constant electrical microcurrent and the resulting electrical field to produce sustainable and rapid improvements in heart failure patients. The company has already demonstrated the unprecedented success of its dilated cardiomyopathy therapy in a first-in-human pilot study.

开发了一种名为“C-MIC”（心脏微电流）的革命性可植入设备，该设备利用持续的电微流和由此产生的电场，为心力衰竭患者带来可持续且快速的改善。该公司已经在一项首次人体试验中展示了其扩张型心肌病治疗的空前成功。

Recently, the company presented the long-term sustainable results of this study at the Technology and Heart Failure Therapeutics (THT) conference on February 11th in Boston and plans to publish the findings in an upcoming journal..

最近，该公司在 2 月 11 日于波士顿举行的技术与心力衰竭治疗学（THT）会议上公布了这项研究的长期可持续结果，并计划在即将出版的期刊上发表这些发现。

Dr. Felix Baader, Chairman of the Board, Berlin Heals says, 'I had the pleasure of meeting several patients together with Co-Founder Marko Bagaric from our first two studies and can see the real impact our innovation has had on returning significant quality of life to them. They were so grateful to have their lives back and be active again.

柏林治愈的董事会主席菲利克斯·鲍德博士说：“我有幸与联合创始人马尔科·巴加里奇一起会见了我们前两项研究中的几位患者，可以看到我们的创新对恢复他们的生活质量所产生的真正影响。他们非常感激能够重获新生并再次活跃起来。

With this funding round, we further our progress to impact many more lives ahead.'.

通过这一轮融资，我们将进一步推进我们的进展，影响更多人的生活。

To reach these next milestones, the company has successfully raised over CHF 7 million in a Series A1 round with existing and new investors in a recently executed financing round. This funding will support First-In-Human studies to evaluate the safety and efficacy of these new approaches to prepare for the large pivotal trial for global regulatory and reimbursement approvals.

为了达成这些下一个里程碑，该公司在最近完成的一轮融资中，成功通过A1轮融资从现有和新投资者那里筹集了超过700万瑞士法郎。这笔资金将用于支持首次人体研究，以评估这些新方法的安全性和有效性，为全球监管和报销批准的大规模关键试验做准备。

This funding will also support further development of the product and preparation for CE submission for the first-generation device..

这笔资金还将支持产品的进一步开发，并为第一代设备的CE提交做准备。

John Brumfield, Chief Executive Officer, Berlin Heals comments, 'We are very grateful to our internal investors that continue to support our mission to heal Heart Failure. We are also excited to welcome our new investors that have joined us on this journey. The results from our early clinical work showed strong potential for this new therapeutic approach.

柏林治疗的首席执行官约翰·布鲁姆菲尔德评论道：“我们非常感谢一直支持我们治疗心力衰竭使命的内部投资者。我们也非常高兴欢迎加入我们这一旅程的新投资者。我们早期临床工作的结果表明，这种新的治疗方法具有强大的潜力。”

We are excited to share the results of our new Randomized Clinical Trial later this year. This funding round will give us the opportunity to test the method through several new less invasive approaches to determine which technique should be used in our Pivotal Trial for FDA and global market entry..

我们很高兴在今年晚些时候分享我们的新的随机临床试验的结果。这一轮融资将使我们有机会通过几种新的微创方法来测试该方法，以确定在我们用于FDA和全球市场准入的关键试验中应使用哪种技术。

(Press release/RAN)

（新闻稿/拉美通讯社）

Image Berlin Heals

柏林治愈图像

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送